NEWS: New Adaptivo Software with 510(k) Clearance, now Officially Released with CE Mark

Oct 18, 2016

(Middleton, WI), October 19, 2016 - Standard Imaging, Inc., a global leader in quality assurance for cancer treatment, announced the official release of their new AdaptivoTM software with CE Mark for sale in Europe. Hailed as the future of patient dosimetry, Adaptivo is the first - and only - software that provides a true picture of the patient and dose at each stage of radiation therapy treatment.

Adaptivo was first announced in late 2015 with FDA 510(k) clearance for sale in the United States and garnered considerable attention. The first of its kind, Adaptivo tracks the dosimetric effect of changes in patient anatomy and position on the treatment plan - giving Medical Physicists the information they need to provide the best care possible. The latest iteration of the software, which has just been released, promises to be even better.

"We've added some important new capabilities, and given the software a bold new look," noted President & CEO Ed Neumueller, "If you thought Adaptivo was impressive before, you should see it now."

The latest version of Adaptivo features a modern web-based user interface, plus improved automation and compatibility. All of this is presented with a customizable home screen and easy navigation.

"Adaptivo provides information no other software can," stated Eric DeWerd, Vice President of Sales and Marketing, "and with the new interface, everything you need is right at your fingertips. It makes tracking how a patient changes over the course of treatment easy."

Standard Imaging is a leading manufacturer of radiation calibration and quality assurance instruments for healthcare. The company was founded in 1989, and has become a leader in the medical physics field. Standard Imaging is committed to the fight against cancer by offering a suite of products aimed at supporting radiation therapy for cancer treatment.

Presented at the 2017 American Society for Radiation Oncology Annual Meeting.